NCT05454761

Brief Summary

The proposed study will be a randomized, assessor-blind controlled trial embedding both outcome and process evaluations of a 6-week group LM intervention with/without self-tracking tools (Study I). The outcome evaluation will examine the effects of LM-S and LM alone vs. CAU, and the process evaluation will enhance the understanding of the causal assumptions that underpin LM to inform policy and clinical practice. Eligible participants with at least a moderate level of depression will be randomly assigned to the LM- S, LM alone, and CAU groups in a 1:1:1 allocation ratio. The study period will be 18 weeks. Assessments at baseline, week 7 (1-week post-intervention), and week 18 (12-week post-intervention) will be managed by an independent assessor (a research assistant, RA) who is blind to the group allocation. The proposed trial and the nested pilot study will follow the CONSORT and STROBE guidelines, respectively. The intervention will be provided free of charge.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
141

participants targeted

Target at P50-P75 for not_applicable depression

Timeline
Completed

Started Jan 2022

Typical duration for not_applicable depression

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2022

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

July 8, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 12, 2022

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

July 12, 2022

Status Verified

July 1, 2022

Enrollment Period

2.7 years

First QC Date

July 8, 2022

Last Update Submit

July 11, 2022

Conditions

Keywords

Lifestyle MedicineDepression

Outcome Measures

Primary Outcomes (1)

  • Change in the Patient Health Questionnaire (PHQ-9)

    The PHQ-9, a 20-item questionnaire used for screening, diagnosing, monitoring and measuring the severity of depression, which scores each of the nine DSM-IV criteria as "0" (not at all) to "3" (nearly every day).

    [Time Frame: Baseline, immediately after treatment, and 12 weeks after the treatment sessions are completed]

Secondary Outcomes (5)

  • Change in Insomnia Severity Index (ISI)

    [Time Frame: Baseline, immediately after treatment, and 12 weeks after the treatment sessions are completed]

  • Change in the Health-Promoting Lifestyle Profile (HPLP II)

    [Time Frame: Baseline, immediately after treatment, and 12 weeks after the treatment sessions are completed]

  • Change in the Sheehan Disability Scale (SDS)

    [Time Frame: Baseline, immediately after treatment, and 12 weeks after the treatment sessions are completed]

  • Change in Quality-adjusted Life Years - The Short Form Six-Dimension (SF-6D)

    [Time Frame: Baseline, immediately after treatment, and 12 weeks after the treatment sessions are completed]

  • Change in Hospital Anxiety and Depression Scale (HADS)

    [Time Frame: Baseline, immediately after treatment, and 12 weeks after the treatment sessions are completed]

Other Outcomes (2)

  • Change in the Credibility-Expectancy Questionnaire (CEQ)

    [Time Frame: Baseline and immediately after treatment]

  • Treatment Acceptability Scale (TAS)

    [Time Frame: Baseline and immediately after treatment]

Study Arms (3)

Lifestyle medicine intervention with self-tracking tools

EXPERIMENTAL

Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness. Self-tracking tools including a smartphone application and an Actigraphy will be given.

Behavioral: Group-based Lifestyle Medicine Program

Pure lifestyle medicine intervention

EXPERIMENTAL

Lifestyle intervention including diet, sleep, exercise, relaxation, and mindfulness.

Behavioral: Group-based Lifestyle Medicine Program

Care-As-Usual

NO INTERVENTION

continue receiving the routine care as usual and be given a smartphone-based LM intervention after the completion of follow-up assessments

Interventions

Participants will receive four core modules that focus on lifestyle modifications. Core Module 1 will be Diets and Nutrition. This module aims to provide simple and evidence-based information regarding nutrition for improving and maintaining mental health. Core Module 2 will be Physical Activity. Participants will practice various types of gentle and adaptable exercises during the session and learn simple ways to incorporate exercise into their daily lives. Core Module 3 will be Sleep Management. This module will include basic facts about sleep, with a focus on psychoeducation on insomnia and how the relationship between circadian and social rhythms relate to sleep and mental health. Core Module 4 will be Stress Management. This module will include psychoeducation about stress, worry management, the cultivation of positive psychology, and relaxation techniques such as diaphragmatic breathing and progressive muscle relaxation.

Lifestyle medicine intervention with self-tracking toolsPure lifestyle medicine intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • at least 18 years of age
  • Cantonese language fluency and readability
  • a PHQ-9 score of at least 10, indicating a moderate level of depression
  • current DSM-IV diagnostic criteria of major depressive episode based on the Mini International Neuropsychiatric Interview (MINI)
  • possession of an internet-enabled mobile device (iOS or Android operating system)
  • willingness to provide informed consent and comply with the trial protocol.

You may not qualify if:

  • the presence of other current psychiatric disorders as assessed by the MINI
  • any medical or neurocognitive disorder(s) that makes participation unsuitable based on the team's clinical experience or interferes with adherence to the lifestyle modification (e.g., where exercise or a change in diet are not recommended by physicians)
  • current serious suicidal risk (non-fleeting intent or plan) as assessed by a PHQ-9 Item 9 score \> 2 (referral information to professional mental health services will be provided)
  • current involvement in lifestyle changes supervised by professionals
  • intake of medication or current participation in any psychotherapy for depression
  • pregnancy
  • hospitalization
  • current participation in any other trial(s).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Chinese University of Hong Kong

Shatin, Hong Kong

RECRUITING

MeSH Terms

Conditions

Depression

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

July 8, 2022

First Posted

July 12, 2022

Study Start

January 1, 2022

Primary Completion

September 1, 2024

Study Completion

December 1, 2024

Last Updated

July 12, 2022

Record last verified: 2022-07

Locations